KR950008531A - 11-벤즈알독심-17β-메톡시-17α-메톡시메틸-에스트라디엔 유도체, 이의 제조방법 및 이를 함유하는 약제 - Google Patents

11-벤즈알독심-17β-메톡시-17α-메톡시메틸-에스트라디엔 유도체, 이의 제조방법 및 이를 함유하는 약제 Download PDF

Info

Publication number
KR950008531A
KR950008531A KR1019940020993A KR19940020993A KR950008531A KR 950008531 A KR950008531 A KR 950008531A KR 1019940020993 A KR1019940020993 A KR 1019940020993A KR 19940020993 A KR19940020993 A KR 19940020993A KR 950008531 A KR950008531 A KR 950008531A
Authority
KR
South Korea
Prior art keywords
phenyl
methoxymethyl
methoxy
estra
dien
Prior art date
Application number
KR1019940020993A
Other languages
English (en)
Other versions
KR100190775B1 (ko
Inventor
슈베르트 게르트
카우프만 귄터
소벡 로타르
오에텔 미카엘
엘거 발터
쿠리쉬코 아나톨리
Original Assignee
디터 타우베르트,칼-하인츠 비티히
예나파름 게엠베하
칼-하인츠 비티히
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디터 타우베르트,칼-하인츠 비티히, 예나파름 게엠베하, 칼-하인츠 비티히 filed Critical 디터 타우베르트,칼-하인츠 비티히
Publication of KR950008531A publication Critical patent/KR950008531A/ko
Application granted granted Critical
Publication of KR100190775B1 publication Critical patent/KR100190775B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 하기 일반식(Ⅰ)의 신규 11-벤즈알독심-에스트라-디엔 유도체 및 약제학적으로 허용가능한 이의 염, 이의 제조방법 및 이를 함유하는 약제에 관한 것이다.
상기 식에서, Z는 -CO-CH3, -CO-O-C2H5, -CO-NH-페닐, -CO-NH-C2H5, -CO-C2H5, -CH3또는 CO-페닐이다.
전술한 화합물은 강한 항게스타겐성 효과와 감소된 글루코코르티코이드 활성을 나타낸다.

Description

11-벤즈알독심-17β-메톡시-17α-메톡시메틸-에스트라디엔 유도체, 이의 제조 방법 및 이를 함유하는 약제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 하기 일반식(Ⅰ)의 11β-벤즈알독심-에스트라-4, 9-디엔유도체 및 약제학적으로 허용가능한 이의 염.
    상기 식에서, Z는 -CO-CH3, -CO-O-C2H5, -CO-NH-페닐, -CO-NH-C2H|5, -CO-C2H5, -CH3또는 CO-페닐이다.
  2. 제1항에 있어서, 11β-〔4-(아세톡시미노메틸)페닐〕-17β-메톡시-17α-메톡시메틸-에스트라-4, 9-디엔-3-온, 11β-{4-〔(아세톡시카보닐)옥시미노메틸〕페닐}-17β-메톡시-17α-메톡시메틸-에스트라-4, 9-디엔-3-온, 11β-{4-〔(에틸아미노카보닐)옥시미노메틸〕페닐}-17β-메톡시-17α-메톡시메틸-에스트라-4, 9-디엔-3-온, 17β-메톡시-17α-메톡시메틸-11β-{4-〔(페닐아미노카보닐)옥시미노메틸〕페닐}-에스트라-4, 9-디엔-3-온, 11β-〔4-(프로피오닐옥시미노메틸)페닐〕-17β-메톡시-17α-메톡시메틸-에스트라-4, 9-디엔-3-온, 11β-〔4-(메틸옥시미노메틸)페닐〕-17β-하이드록시-17α-메톡시메틸-에스트라-4, 9-디엔-3-온 및 11β-〔4-(벤조일옥시미노메틸)페닐〕-17β-하이드록시-17α-메톡시메틸-에스트라-4, 9-디엔-3-온인 화합물.
  3. 하기 구조식(Ⅱ)의 화합물을 일반적으로 공지된 방법으로 에스테르화 또는 에테르화하고, 필요한 경우, 염으로 전환시킴을 특징으로 하여, 제1항에 다른 일반식(Ⅰ)의 화합물 및 약제학적으로 허용가능한 이의 염을 제조하는 방법.
    상기 식에서, Z는 -CO-CH3, -CO-O-C2H5, -CO-NH-페닐, -CO-NH-C2H5, -CO-C2H5, -CH3또는 CO-페닐이다.
  4. 제1항 또는 제2항에 따른 화합물 하나 이상을 함유함을 특징으로 하는 약제학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940020993A 1993-09-20 1994-08-25 11베타-벤즈알독심-에스트라-4,9-디엔유도체, 이의 제조방법 및 이를 함유하는 약제학적 조성물 KR100190775B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4332284.0 1993-09-20
DE4332284A DE4332284C2 (de) 1993-09-20 1993-09-20 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel

Publications (2)

Publication Number Publication Date
KR950008531A true KR950008531A (ko) 1995-04-19
KR100190775B1 KR100190775B1 (ko) 1999-06-01

Family

ID=6498354

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940020993A KR100190775B1 (ko) 1993-09-20 1994-08-25 11베타-벤즈알독심-에스트라-4,9-디엔유도체, 이의 제조방법 및 이를 함유하는 약제학적 조성물

Country Status (19)

Country Link
EP (1) EP0648779B1 (ko)
JP (1) JP2696672B2 (ko)
KR (1) KR100190775B1 (ko)
AT (1) ATE149513T1 (ko)
AU (1) AU682373B2 (ko)
CA (1) CA2130515C (ko)
CZ (1) CZ289801B6 (ko)
DE (2) DE4332284C2 (ko)
DK (1) DK0648779T3 (ko)
ES (1) ES2102144T3 (ko)
FI (1) FI112948B (ko)
GR (1) GR3023644T3 (ko)
HU (1) HU219399B (ko)
NO (1) NO304988B1 (ko)
NZ (1) NZ264228A (ko)
PL (1) PL179460B1 (ko)
RU (1) RU2130944C1 (ko)
SK (1) SK280315B6 (ko)
UA (1) UA39101C2 (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5576310A (en) * 1994-09-20 1996-11-19 Jenapharm Gmbh 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
DE19745085A1 (de) * 1997-10-11 1999-04-15 Jenapharm Gmbh 11ß-Benzaldoxim-9alpha,10alpha-epoxy-estr-4-en-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
DE19809845A1 (de) 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
DE19906152B4 (de) 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
US7629334B1 (en) * 1999-08-31 2009-12-08 Bayer Schering Pharma Aktiengesellschaft Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
PL353994A1 (en) * 1999-08-31 2003-12-15 Jenapharm Gmbh & Co.Kgjenapharm Gmbh & Co.Kg Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
CZ301412B6 (cs) 1999-08-31 2010-02-24 Bayer Schering Pharma Aktiengesellschaft Použití specifických mesoprogestinu jako farmaceutické složky pro výrobu léciva pro hormonální substitucní lécbu
KR100864547B1 (ko) 1999-08-31 2008-10-20 바이엘 쉐링 파마 악티엔게젤샤프트 양성 호르몬 의존성 부인과 질병의 치료 및 예방을 위한메조프로게스틴 (프로게스테론 수용체 조절물질)
DE19961219A1 (de) * 1999-12-15 2001-07-19 Jenapharm Gmbh 11beta-Phenylestratrien-Derivate mit Fluoralkylgruppen in der aromatischen Seitenkette, deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE10056677A1 (de) * 2000-11-10 2002-05-16 Jenapharm Gmbh Verfahren zur Herstellung von 4-(17a-Alkoxymethyl-17ß-substituierten-3-oxoestra-4,9-dien-11ß-yl)benzaldehyd-(1E)-oxim-Derivaten
DE10056676A1 (de) * 2000-11-10 2002-05-16 Jenapharm Gmbh Verfahren zur Herstellung von 4-/17alpha-substituierten-3-oxoestra-4,9-dien-11beta-yl)benzaldehyd-(1E oder 1Z)-oximen
EP1285927A3 (de) * 2001-08-16 2005-06-29 Schering Aktiengesellschaft Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
DE10221034A1 (de) 2002-05-03 2003-11-20 Schering Ag 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
EP1525215B1 (de) * 2002-08-02 2006-09-06 Schering Aktiengesellschaft Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
DE102005059222B4 (de) * 2005-12-08 2007-10-11 Bayer Schering Pharma Ag 11ß-Benzaldoximderivate von D-Homoestra-4,9-dien-3-onen
SI3263112T1 (sl) 2006-10-24 2020-10-30 Allergan Pharmaceuticals International Limited Sestavki in metode za zaviranje endometrijskih proliferacij
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
KR102166867B1 (ko) 2010-03-22 2020-10-19 앨러간 파마슈티컬스 인터내셔널 리미티드 항프로게스틴의 비독성 전달을 위한 조성물들과 그 방법들

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU580843B2 (en) * 1985-02-07 1989-02-02 Schering Aktiengesellschaft 11``-phenyl-gonanes, their manufacture and pharmaceutical preparations containing them
DE3504421A1 (de) * 1985-02-07 1986-08-07 Schering AG, 1000 Berlin und 4709 Bergkamen Neue 11ss-phenyl-gonane, deren herstellung und diese enthaltende pharmazeutische praeparate
EP0411733B1 (de) * 1989-08-04 1998-10-21 Schering Aktiengesellschaft 11 Beta-Aryl-gona-4,9-dien-3-one
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel

Also Published As

Publication number Publication date
HUT68315A (en) 1995-06-28
NO304988B1 (no) 1999-03-15
HU9402695D0 (en) 1994-11-28
CZ289801B6 (cs) 2002-04-17
NZ264228A (en) 1995-04-27
UA39101C2 (uk) 2001-06-15
CA2130515C (en) 2001-07-17
FI943688A (fi) 1995-03-21
FI943688A0 (fi) 1994-08-09
CZ196994A3 (en) 1995-04-12
JP2696672B2 (ja) 1998-01-14
CA2130515A1 (en) 1995-03-21
ES2102144T3 (es) 1997-07-16
EP0648779B1 (de) 1997-03-05
DE4332284A1 (de) 1995-03-23
EP0648779A3 (de) 1995-08-09
ATE149513T1 (de) 1997-03-15
PL179460B1 (pl) 2000-09-29
RU94029667A (ru) 1996-06-27
SK95894A3 (en) 1995-04-12
AU682373B2 (en) 1997-10-02
NO942952L (no) 1995-03-21
DE4332284C2 (de) 1997-05-28
JPH07149790A (ja) 1995-06-13
NO942952D0 (no) 1994-08-09
EP0648779A2 (de) 1995-04-19
SK280315B6 (sk) 1999-11-08
DE59401919D1 (de) 1997-04-10
FI112948B (fi) 2004-02-13
HU219399B (hu) 2001-04-28
KR100190775B1 (ko) 1999-06-01
PL305091A1 (en) 1995-04-03
RU2130944C1 (ru) 1999-05-27
DK0648779T3 (da) 1997-09-15
GR3023644T3 (en) 1997-08-29
AU7035194A (en) 1995-03-30

Similar Documents

Publication Publication Date Title
KR950008531A (ko) 11-벤즈알독심-17β-메톡시-17α-메톡시메틸-에스트라디엔 유도체, 이의 제조방법 및 이를 함유하는 약제
FI934274A0 (fi) N-sulfonyl-2-oxi-indolderivat, deras framstaellning och dessa innehaollande farmaceutiska kompositioner
PH23739A (en) Piperidine derivative and pharmaceutical composition
KR950017949A (ko) 벤조티오펜 화합물과 수용성 사이클로덱스트린의 수용성 내포착물, 및 그의 약학제제 및 제조 방법
KR970706021A (ko) N-치환-o-톨루이딘유도체로 이루어진 약용배합제 및 경피흡수형제제(MEDICINAL ADJUVANTS CONSISTIONG OF AN N-SUBSTITUED-o-TOLUIDING DERIVANTIVE, AND PERCUTANEOUSLY ABSORBALE PREPARATIONS COMPRISING THE ADJUVANTS)
KR920021517A (ko) 중축 신경계에 활성인 신규의 3-아미노피리다진 유도체, 그의 제조방법 및 이들의 존재하는 약제학적 조성물
KR950016722A (ko) Ldl 산화 및 죽상동맥경화증의 억제 방법
KR920703512A (ko) 단백질 활성효소 c(protein kinase c)를 방해하는 1, 4-비스-(아미노-하이드록시알킬아미노)-안트라퀴논
KR960007592A (ko) 신규한 피롤로카바졸
KR930016436A (ko) 4, 13-디옥사바이사이클로[8.2.1]트리데세논유도체와 그의 제조방법, 그의 제조를 위한 중간체 및 이화합물이 함유된 약학조성물
KR950011462A (ko) 호르몬 활성이 저하된 에스트라디올 유도체-알킬화제 결합체, 그의 제조방법, 그의 제조에 유용한 화합물, 및 상기 결합체 또는 에스트라디올 유도체를 함유하는 성장억제조성물
KR930016402A (ko) 항-hiv 활성을 갖는 이미다졸 유도체
KR900009606A (ko) 불소-함유 2-니트로 이미다졸 유도체 및 그를 함유하는 방사선 증감제
KR900018048A (ko) 환 치환된 2-아미노-1,2,3,4-테트라하이드로나프탈렌
KR950016735A (ko) 터너 증후군의 억제 방법
KR900001715A (ko) Bu-3608 유도체
KR890001965A (ko) 스퍼구알린 관련 유도체
KR900003177A (ko) 테트라시클릭계 우울증 치료제
KR900016178A (ko) 2-치환 n,n'-디트리메톡시벤조일 피페라진, 그의 제조 방법 및 그를 함유하는 치료 조성물
CA2010982A1 (en) Osteogenesis promotion with use of vitamin d derivatives
KR900012925A (ko) 인돌 유도체
KR890008148A (ko) 새로운 세파로스포린 화합물 및 항균제
KR890008121A (ko) 로다닌 유도체 및 약제학적 조성물
KR960703940A (ko) 에스트라디올의 15,15-디알킬 치환 유도체(15,15-Dialkyl-Substituted Derivatives of Estradiol)
KR850000415A (ko) 퀴나졸리논 유도체의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20100112

Year of fee payment: 12

LAPS Lapse due to unpaid annual fee